Skip to main content

Table 3 Prognostic value of KRAS status analyzed in tumor tissue and plasma by different laboratory assays in colorectal cancer patients

From: KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

    Prognostic value
Tissue and testing method    PFS OS
KRASstatus   Median PFS (mo) 95% Cl Pvalue* Median OS (mo) 95% Cl Pvalue*
Tumor         
Sequencing Wild-type 260 6·1 4·5-7·7 ·473 18·3 16·2-20·4 ·064
Mutated 156 5·8 3·4-8·2 15·9 14·4-17·4
PNA-PCR Wild-type 221 6·2 4·5-7·9 ·360 19·5 17·2-21·8 ·025
Mutated 195 5·9 4·0-7·8 16·9 15·6-18·2
Plasma         
Sequencing Wild-type 201 6·1 5·5-6·6 ·489 18·3 15·9-20·7 ·037
Mutated 41 5·4 4·9-5·8 15·7 9·3-22·1
PNA-PCR Wild-type 166 6·1 5·5-6·7 ·274 19·1 16·8-21·4 ·009
Mutated 76 5·7 5·3-6·1 15·7 13·0-18·4
  1. *Log-rank test. All statistical tests were two-sided.
  2. CI, confidence interval; mo, month; OS, overall survival; PFS, progression-free survival; PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.